Roche Teams With QB3 To Incubate Life-Science Start-Ups In Bay Area
This article was originally published in The Pink Sheet Daily
The pharma and the incubator’s venture arm will provide seed funding for start-ups emerging from their collaborative efforts. Later, Roche may participate in Series A funding or even opt in to buy programs or whole companies.
You may also be interested in...
Pfizer Inc.’s latest pledge to academic research, a five-year $85 million agreement to fund projects at the University of California, San Francisco, isn’t just a deepening of the Big Pharma’s commitment to on-campus studies intended to bridge the so-called Valley of Death between the laboratory and the commercial sector. It’s also a sign of the increased importance of deals between pharmas and universities, which give commercial partners access to new research earlier in the development process while nudging academics toward projects with commercial relevance in mind.
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.
Results showed that patients were less likely to exhibit disease progression, or die, following treatment with beta-emitted microspheres.